An anti-malaria compound illuminates a option to deal with polycystic ovary syndrome | Health & Wellness | EUROtoday

Get real time updates directly on you device, subscribe now.

Artemis was, in response to Greek mythology, the deity of looking, births and virginity, protector of childbirth and fertility. Depicted in artwork with a bow in her hand and a fawn at her toes, the goddess has additionally given her identify to an previous plant with recognized medicinal properties: artemisia, with therapeutic results in opposition to malaria and, in response to latest analysis, might past her. In a stunning crossover between science and mythology, a scientific examine has illuminated a brand new impact of an artemisia compound that evokes, greater than ever, the destiny of the goddess: an article printed this Thursday within the journal Science suggests {that a} by-product of those vegetation additionally has the potential to alleviate the signs of polycystic ovary syndrome, a fancy hormonal dysfunction that impacts as much as 13% of girls of reproductive age and might trigger, amongst different issues, alterations within the menstrual cycle. , metabolic issues, zits or infertility.

Chinese medication has been conscious, for greater than two millennia, of the therapeutic potential of vegetation of the genus Artemisia: within the sixteenth century, for instance, qing hao tea (Artemisia annual or candy wormwood) to deal with the signs of malaria. Since then, science has scrutinized these vegetation to know their properties and has revealed that one in all their compounds, artemisinin, additionally has the flexibility to enhance power expenditure and insulin sensitivity. The new examine by researchers at Fudan University (in Shanghai, China) delves into these advantages and examines their competence in treating polycystic ovary syndrome, a dysfunction linked to metabolic dysfunction and characterised by extreme manufacturing of androgens, the hormones male signs that additionally happen, though to a lesser extent, in ladies. In experiments with animals and in a pilot trial with 19 sufferers, scientists have confirmed that an artemisinin compound manages to cease the extreme manufacturing of androgens and, thereby, scale back the signs related to this situation. The discovery opens the door to a brand new remedy for a really heterogeneous pathology with very restricted therapeutic choices.

Polycystic ovary syndrome is a typical endocrine dysfunction, one of the vital widespread in gynecology consultations, explains Ana Robles, a gynecologist on the Hospital del Mar in Barcelona and a specialist in endocrinology and human copy. “It is usually diagnosed in adulthood. Patients usually consult for menstrual disorders or fertility problems,” she says. The important attribute of this dysfunction is the extreme manufacturing of androgens within the ovaries (hyperandrogenism), which causes a variety of related signs, resembling elevated hair, alopecia, zits, irregular menstrual cycles or metabolic issues (there’s a excessive prevalence of weight problems). amongst sufferers). In the long run, in addition they have a better threat of heart problems, diabetes or hypertension. “Different pathways or causes of polycystic ovary syndrome have been described, but it is surely multifactorial. There will be a genetic basis and intrauterine environmental factors and other situations will influence it, such as obesity,” explains Robles.

Furthermore, it’s a tremendously heterogeneous dysfunction and, in all probability, that’s what makes it obscure its origin, emphasizes Gemma Casals, a gynecologist within the Human Reproduction part of the Hospital Clínic of Barcelona: “There are questions. It is not well known how the syndrome develops and there is speculation that perhaps it does not always develop the same way,” she displays.

For the analysis, says Casals, docs take a look at “three cardinal points”: menstrual cycle problems, the looks of the ovaries and the rise in androgens. In these sufferers, there are normally alterations in menstruation and the ovaries have a specific morphology: they’re normally bigger in quantity and have many antral follicles, that are a sort of sac with immature eggs inside. Excess androgens are additionally confirmed by exams and scales that measure extra hair in additional androgynous areas, such because the chin, buttocks or again, for instance.

The instruments obtainable to deal with this medical situation are restricted and are basically aimed toward relieving signs. Thus, to the advice of wholesome life-style habits and weight discount, contraceptives are added, above all, which management hormonal manufacturing, enhance signs and regulate menstruation. But these therapies don’t clear up the issue comprehensively. In truth, they don’t enhance infertility or the morphology of the polycystic ovary, the authors of the examine add.

The versatility of artemisinins

In this context of a restricted therapeutic arsenal and restricted efficacy, the Fudan University examine opens the door to a brand new avenue of remedy and explores the flexibility of artemisinin. “It has shown great promise in various applications with minimal adverse effects, such as the treatment of malaria, cold, diarrhea, lupus erythematosus and cancer. Our previous findings showed that artemisinins promoted homeostasis [equilibrio] metabolic and protected against obesity, which led us to investigate whether they could regulate the development of polycystic ovary syndrome,” the authors justify in the article.

Qi-qun Tang, principal investigator of the study, explains in an email response that if excess androgens are the main driver of numerous characteristics of this disorder, “controlling the excess is crucial to intervene” on this pathology. And artemisinin can do it. In mice, scientists found that artemether, a by-product of artemisinin, reduces the manufacturing of ovarian androgens by affecting a key enzyme for the manufacture of those hormones. As a end result, “considerable improvements” had been discovered, the analysis factors out, in irregular cycles, the morphology of the polycystic ovary and the low fertility of the animals.

The scientists then took these initial findings to a small pilot clinical trial with 19 women and found that by taking dihydroartemisinin (a medication used for malaria) for 12 weeks, PCOS biomarkers were reduced and menstrual cycles were reduced. they normalized. “Our findings highlight the promising potential of artemisinins as effective drugs for the comprehensive treatment of polycystic ovary syndrome,” the authors conclude in the scientific article. The researchers admit, however, some limitations in the research, such as the animal model used, which does not exactly replicate “the advanced circumstances of polycystic ovary syndrome in ladies.”

Promising approach

In an analysis accompanying the study, Elisabet Stener-Victorin, a researcher at the Department of Physiology and Pharmacology at the Karolinska Institute in Sweden, considers that the discovery of artemisinins as a remedy against the symptoms of polycystic ovary is a “promising approach” in this pathology. “This advance not only highlights the versatility of artemisinins, but also has great potential to improve the quality of life of millions of affected women, representing an important advance in reproductive medicine,” she reflects. Along the same lines, Robles, who has not participated in the research either, adds: “It is a pilot clinical trial, but everything that is basic research on the pathways and knowing which proteins and enzymes are involved opens the door to designing target drugs for improve treatment.”

For his part, Casals, who has also published a study on the impact of bariatric surgery in patients with obesity and polycystic ovary syndrome to reduce the symptoms of this hormonal disorder, maintains that Tang's study is a first step and, although More confirmatory research is required, it is “good news.” “This compound not only reduces testosterone levels, which is the main androgen, but also reduces menstrual cycles and the polycystic appearance of the ovary. And in animal models, it manages to improve embryo implantation. The authors also end up doing a pathophysiological study and determining why they work: the enzyme that inhibits artemisinin has effects on androgens,” he explains.

María Jesús Cancelo, spokesperson for the Spanish Society of Gynecology and Obstetrics, points out that Tang's study presents “an interesting approach.” “The current availability of treatments is based on treating the symptoms and what these authors propose is to treat the cause, to reduce the production of androgens from the ovary itself. The investigations are very initial and we must be cautious, but it seems very promising,” she says. Tang assures that they are currently “extending the observation period [a las participantes del estudio] to determine if there is a relapse after a longer period without the medication.” In addition, they are working to refine the dose and duration of treatment to later begin a larger trial.

You can follow EL PAÍS Health and Wellbeing in Facebook, X e Instagram.